Historical record - last NADAC effective date: 2/17/2021
Product Information
VENLAFAXINE HCL ER 150 MG CAP is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.1883 per EA under NDC 68382003606. Its NADAC has been published 379 times since Nov 28, 2013.
FDA first approved this application on Apr 14, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382003606
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
2/17/2021
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090174FDA Approved
4/14/2011
TE Code
AB
On Market Since
6/1/2011
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL ER 150 MG CAP has been published 379 times since Nov 28, 2013, and over the history we have for it it has declined 5.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1883 per EA |
|---|---|
| All-time high | $0.3504 (Mar 12, 2014) |
| All-time low | $0.1557 (Apr 18, 2018) |
| Median price | $0.1863 |
| Average price | $0.1919 |
| Largest weekly change | -32.5% (Apr 23, 2014) |
| Weeks tracked | 379 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-5.9%
Last surveyed Feb 24, 2021 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 37% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
venlafaxine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL ER 150 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL ER 150 MG CAP, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.1883 per EA (NDC 68382003606), effective Feb 24, 2021.
How has the price of VENLAFAXINE HCL ER 150 MG CAP changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has declined 5.9%. It has been tracked across 379 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL ER 150 MG CAP?
Since Nov 28, 2013, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has ranged from a low of $0.1557 (Apr 18, 2018) to a high of $0.3504 (Mar 12, 2014), with a median of $0.1863 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL ER 150 MG CAP?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VENLAFAXINE HCL ER 150 MG CAP, is $0.1190 per EA — about 37% below VENLAFAXINE HCL ER 150 MG CAP.
Who manufactures VENLAFAXINE HCL ER 150 MG CAP?
VENLAFAXINE HCL ER 150 MG CAP (NDC 68382003606) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.